BeOne Medicines Ltd. (ONC) Insider Trading

Last 12 months

Insiders sold $380M and bought nothing on the open market.

96% of the selling was scheduled in advance under 10b5-1 plans. President and COO Xiaobin Wu sold $5.85M on Nov 13, 2025 outside a plan. The last open-market buy by an executive or director was in Nov 2016.

Net open-market

−$380M

0 buys · 50 sales

Under a 10b5-1 plan

96%

of the value sold

Insiders who bought / sold

0 / 11

executives and directors

Last open-market buy

Nov 2016

Nov 23, 2016

Get an email when ONC's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 13	Xiaodong Wang Director	Sold10b5-1 plan 5 parts	31,027	$350.99 average	$10.9M	0.5%	Form 4
Sep 30	Chan Henry Lee SVP, General Counsel	Sold10b5-1 plan	1,115	$375.00	$418k	0.4%	Form 4
Sep 28	Xiaodong Wang Director	Sold10b5-1 plan 10 parts	31,028	$364.79 average	$11.3M	0.4%	Form 4
Sep 8	Xiaodong Wang Director	Sold10b5-1 plan 8 parts	38,287	$349.10 average	$13.4M	0.7%	Form 4
Sep 1	Titus B. Ball Principal Accounting Officer	SoldNo plan	132	$355.86	$47k	0.1%	Form 4
Aug 25	Xiaobin Wu President and COO	Sold10b5-1 plan	280	$380.00	$106k	<0.1%	Form 4
Aug 10 – 12	John Oyler Chief Executive Officer	Sold10b5-1 plan 24 parts	240,810	$359.12 average	$86.5M	2.1%	Form 4
Aug 11	Chan Henry Lee SVP, General Counsel	Sold10b5-1 plan	2,666	$360.00	$960k	0.8%	Form 4
Aug 3	Aaron Rosenberg Chief Financial Officer	SoldNo plan	1,157	$312.72	$362k	0.3%	Form 4
Jul 30	Chan Henry Lee SVP, General Counsel	SoldNo plan	1,044	$323.69	$338k	0.3%	Form 4
Jul 22	Chan Henry Lee SVP, General Counsel	Sold10b5-1 plan	1,669	$325.00	$542k	0.5%	Form 4
Jul 20 – 21	John Oyler Chief Executive Officer	Sold10b5-1 plan 14 parts	109,713	$315.29 average	$34.6M	0.9%	Form 4
Jul 17	John Oyler Chief Executive Officer	Sold10b5-1 plan 9 parts	64,628	$312.00 average	$20.2M	0.2%	Form 4
Jul 15 – 16	John Oyler Chief Executive Officer	Sold10b5-1 plan 17 parts	283,154	$315.56 average	$89.4M	2.1%	Form 4
Jul 14	John Oyler Chief Executive Officer	Sold10b5-1 plan 6 parts	145,861	$305.95 average	$44.6M	1.0%	Form 4
Jul 10 – 13	John Oyler Chief Executive Officer	Sold10b5-1 plan 15 parts	60,218	$303.18 average	$18.3M	0.2%	Form 4
Jul 8	Chan Henry Lee SVP, General Counsel	Sold10b5-1 plan	664	$302.46	$201k	0.2%	Form 4
Jun 23	Lai Wang President, Global Head of R&D	SoldNo plan	1,068	$276.74	$296k	<0.1%	Form 4
Jun 23	Xiaobin Wu President and COO	SoldNo plan	1,292	$276.26	$357k	0.1%	Form 4
Jun 23	John Oyler Chief Executive Officer	SoldNo plan 3 parts	3,410	$273.78 average	$934k	<0.1%	Form 4
Jun 16	Chan Henry Lee SVP, General Counsel	SoldNo plan	590	$265.98	$157k	0.2%	Form 4
Jun 16	Lai Wang President, Global Head of R&D	SoldNo plan	1,169	$265.39	$310k	<0.1%	Form 4
Jun 16	Xiaobin Wu President and COO	SoldNo plan	1,357	$266.76	$362k	0.1%	Form 4
Jun 16	John Oyler Chief Executive Officer	SoldNo plan 3 parts	3,693	$265.55 average	$981k	<0.1%	Form 4
Jun 11	Aaron Rosenberg Chief Financial Officer	SoldNo plan	631	$257.74	$163k	0.2%	Form 4
Jun 11	Chan Henry Lee SVP, General Counsel	SoldNo plan	428	$257.64	$110k	0.1%	Form 4
Jun 11	Lai Wang President, Global Head of R&D	SoldNo plan	756	$261.00	$197k	<0.1%	Form 4
Jun 11	Xiaobin Wu President and COO	SoldNo plan	626	$261.20	$164k	<0.1%	Form 4
Jun 11	Titus B. Ball Principal Accounting Officer	SoldNo plan 2 parts	169	$257.20 average	$43k	0.2%	Form 4
Jun 11	John Oyler Chief Executive Officer	SoldNo plan 4 parts	1,949	$257.24 average	$501k	<0.1%	Form 4
Jun 8	Chan Henry Lee SVP, General Counsel	SoldNo plan 2 parts	871	$270.43 average	$236k	0.3%	Form 4
Jun 8	Lai Wang President, Global Head of R&D	SoldNo plan 2 parts	1,367	$269.38 average	$368k	<0.1%	Form 4
Jun 8	Xiaobin Wu President and COO	SoldNo plan 2 parts	1,484	$269.36 average	$400k	0.1%	Form 4
Jun 8	Titus B. Ball Principal Accounting Officer	SoldNo plan 2 parts	136	$271.33 average	$37k	0.2%	Form 4
Jun 8	John Oyler Chief Executive Officer	SoldNo plan 2 parts	4,940	$270.55 average	$1.34M	<0.1%	Form 4
Jun 1	Qingqing Yi Director	SoldNo plan	235	$279.13	$66k	1.0%	Form 4
May 22	Margaret Dugan Director	SoldNo plan	212	$309.60	$66k	0.4%	Form 4
May 22	Alessandro Riva Director	SoldNo plan	212	$309.51	$66k	0.4%	Form 4
May 22	Corazon (corsee) D. Sanders Director	SoldNo plan	212	$309.59	$66k	0.4%	Form 4
May 22	Baker Bros. Advisors LP Large holder	SoldNo plan 4 parts	10,998	$23.82 average	$262k	0.1%	Form 4

Oct 1310b5-1 plan
Xiaodong Wang
Director · sold 31,027 at avg $350.99
$10.9M
0.5% of stake
Sep 3010b5-1 plan
Chan Henry Lee
SVP, General Counsel · sold 1,115 at $375.00
$418k
0.4% of stake
Sep 2810b5-1 plan
Xiaodong Wang
Director · sold 31,028 at avg $364.79
$11.3M
0.4% of stake
Sep 810b5-1 plan
Xiaodong Wang
Director · sold 38,287 at avg $349.10
$13.4M
0.7% of stake
Sep 1No plan
Titus B. Ball
Principal Accounting Officer · sold 132 at $355.86
$47k
0.1% of stake
Aug 2510b5-1 plan
Xiaobin Wu
President and COO · sold 280 at $380.00
$106k
<0.1% of stake
Aug 10 – 1210b5-1 plan
John Oyler
Chief Executive Officer · sold 240,810 at avg $359.12
$86.5M
2.1% of stake
Aug 1110b5-1 plan
Chan Henry Lee
SVP, General Counsel · sold 2,666 at $360.00
$960k
0.8% of stake
Aug 3No plan
Aaron Rosenberg
Chief Financial Officer · sold 1,157 at $312.72
$362k
0.3% of stake
Jul 30No plan
Chan Henry Lee
SVP, General Counsel · sold 1,044 at $323.69
$338k
0.3% of stake
Jul 2210b5-1 plan
Chan Henry Lee
SVP, General Counsel · sold 1,669 at $325.00
$542k
0.5% of stake
Jul 20 – 2110b5-1 plan
John Oyler
Chief Executive Officer · sold 109,713 at avg $315.29
$34.6M
0.9% of stake
Jul 1710b5-1 plan
John Oyler
Chief Executive Officer · sold 64,628 at avg $312.00
$20.2M
0.2% of stake
Jul 15 – 1610b5-1 plan
John Oyler
Chief Executive Officer · sold 283,154 at avg $315.56
$89.4M
2.1% of stake
Jul 1410b5-1 plan
John Oyler
Chief Executive Officer · sold 145,861 at avg $305.95
$44.6M
1.0% of stake
Jul 10 – 1310b5-1 plan
John Oyler
Chief Executive Officer · sold 60,218 at avg $303.18
$18.3M
0.2% of stake
Jul 810b5-1 plan
Chan Henry Lee
SVP, General Counsel · sold 664 at $302.46
$201k
0.2% of stake
Jun 23No plan
Lai Wang
President, Global Head of R&D · sold 1,068 at $276.74
$296k
<0.1% of stake
Jun 23No plan
Xiaobin Wu
President and COO · sold 1,292 at $276.26
$357k
0.1% of stake
Jun 23No plan
John Oyler
Chief Executive Officer · sold 3,410 at avg $273.78
$934k
<0.1% of stake
Jun 16No plan
Chan Henry Lee
SVP, General Counsel · sold 590 at $265.98
$157k
0.2% of stake
Jun 16No plan
Lai Wang
President, Global Head of R&D · sold 1,169 at $265.39
$310k
<0.1% of stake
Jun 16No plan
Xiaobin Wu
President and COO · sold 1,357 at $266.76
$362k
0.1% of stake
Jun 16No plan
John Oyler
Chief Executive Officer · sold 3,693 at avg $265.55
$981k
<0.1% of stake
Jun 11No plan
Aaron Rosenberg
Chief Financial Officer · sold 631 at $257.74
$163k
0.2% of stake
Jun 11No plan
Chan Henry Lee
SVP, General Counsel · sold 428 at $257.64
$110k
0.1% of stake
Jun 11No plan
Lai Wang
President, Global Head of R&D · sold 756 at $261.00
$197k
<0.1% of stake
Jun 11No plan
Xiaobin Wu
President and COO · sold 626 at $261.20
$164k
<0.1% of stake
Jun 11No plan
Titus B. Ball
Principal Accounting Officer · sold 169 at avg $257.20
$43k
0.2% of stake
Jun 11No plan
John Oyler
Chief Executive Officer · sold 1,949 at avg $257.24
$501k
<0.1% of stake
Jun 8No plan
Chan Henry Lee
SVP, General Counsel · sold 871 at avg $270.43
$236k
0.3% of stake
Jun 8No plan
Lai Wang
President, Global Head of R&D · sold 1,367 at avg $269.38
$368k
<0.1% of stake
Jun 8No plan
Xiaobin Wu
President and COO · sold 1,484 at avg $269.36
$400k
0.1% of stake
Jun 8No plan
Titus B. Ball
Principal Accounting Officer · sold 136 at avg $271.33
$37k
0.2% of stake
Jun 8No plan
John Oyler
Chief Executive Officer · sold 4,940 at avg $270.55
$1.34M
<0.1% of stake
Jun 1No plan
Qingqing Yi
Director · sold 235 at $279.13
$66k
1.0% of stake
May 22No plan
Margaret Dugan
Director · sold 212 at $309.60
$66k
0.4% of stake
May 22No plan
Alessandro Riva
Director · sold 212 at $309.51
$66k
0.4% of stake
May 22No plan
Corazon (corsee) D. Sanders
Director · sold 212 at $309.59
$66k
0.4% of stake
May 22No plan
Baker Bros. Advisors LP
Large holder · sold 10,998 at avg $23.82
$262k
0.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ONC, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Pharmaceutical Preparations

OGNOrganon & Co.

ELANElanco Animal Health Incorporated

JAZZJazz Pharmaceuticals plc

PRGOPerrigo Company plc

ALNYAlnylam Pharmaceuticals Inc

BMRNBiomarin Pharmaceutical Inc.

UTHRUnited Therapeutics Corporation

AMRXAmneal Pharmaceuticals Inc.

Spot a number that looks wrong? Check it in ONC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ONC

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.